非奈利酮对心血管疾病和慢性肾脏病的影响：对抗心肾疾病发病率和死亡率的新武器——综述
Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review.
作者信息
Piccirillo Francesco, Liporace Paola, Nusca Annunziata, Nafisio Vincenzo, Corlianò Andrea, Magarò Francesca, Antonelli Incalzi Raffaele, Ussia Gian Paolo, Grigioni Francesco
机构信息
Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, Italy.
Research Unit of Cardiovascular Sciences, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Roma, Italy.
出版信息
J Cardiovasc Dev Dis. 2023 May 28;10(6):236. doi: 10.3390/jcdd10060236.
Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes.
患有心血管疾病（CVD）和慢性肾脏病（CKD）的患者出现心肾不良结局的几率很高。此外，随着CKD病情恶化，肾衰竭和心血管事件的进展也会增加。多项研究表明，盐皮质激素受体（MR）的激活会导致心脏和肾脏损伤，包括炎症和纤维化。非奈利酮是一种新型的非甾体类选择性MR拮抗剂（MRA），在临床前研究中已显示出抗炎和抗纤维化作用。此外，两项大型试验（FIDELIO-DKD和FIGARO-DKD）调查了接受非奈利酮治疗的2型糖尿病轻度至重度CKD患者的肾脏和心血管结局。基于这些，本综述旨在总结目前关于非奈利酮及其对CKD和心血管系统影响的知识，强调其在改善心肾结局方面的作用。
Zotero 插件